Superficial and deep lymph node dissection for stage III cutaneous melanoma: Clinical outcome and prognostic factors

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Mozzillo, Nicola ^a   Caracò, Corrado ^b   Marone, Ugo ^b   Di Monta, Gianluca ^b   Crispo, Anna ^d   Botti, Gerardo ^e   Montella, Maurizio ^d   Ascierto, Paolo A ^c  

^a Sarcoma and Skin Cancer ^*  (Italy)

^b Division of Melanoma and Skin Cancer   (Italy)

^c Division of Medical Oncology A   (Italy)

^d Division of Epidemiology   (Italy)

^e Inst of Gen Pathology and Oncology   (Italy)

Author keywords

Cutaneous melanoma; Lymph node metastases; Sentinel biopsy

Indexed keywords

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CUTANEOUS MELANOMA; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; INGUINAL LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SURGICAL TECHNIQUE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GROIN; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84873201556     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-36     Document Type: Article

References (33)

1. White RR, Stanley WE, Johnson JL, Tyler DS, Seigler HF. Long-term survival in 2505 patients with melanoma with regional lymph node metastases. Ann Surg 2002, 235:879-887. 10.1097/00000658-200206000-00017, 1422519, 12035046.
2. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. Ann Surg 1991, 214:627-636. 10.1097/00000658-199111000-00014, 1358620, 1953117.
3. Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989, 124:162-166. 10.1001/archsurg.1989.01410020032004, 2464981.
4. Singletary SE, Shallenberger R, Guinee VF. Surgical management of groin nodal metastases from primary melanoma of the lower extremity. Surg Gynecol Obstet 1992, 174:195-200.
5. Badgwell B, Xing Y, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JN. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol 2007, 14:2867-2872. 10.1245/s10434-007-9512-7, 17671814.
6. Balch CM, Ross M. Melanoma patients with iliac nodal metastases can be cured. Ann Surg Oncol 1999, 6:230-231. 10.1007/s10434-999-0230-1, 10340880.
7. Kuroi K, Shimozuma K, Taguchi T, Imai H, Yamashiro H, Ohsumi S, Saito S. Pathophysiology of seroma in breast cancer. Breast Cancer 2005, 12:288-293. 10.2325/jbcs.12.288, 16286909.
8. Kissin MW, Simpson DA, Easton D, White H, Westbury G. Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma. Br J Surg 1987, 74:1023-1026. 10.1002/bjs.1800741122, 3690228.
9. Jacobs LK, Balch CM, Coit DG. Inguinofemoral, iliac/obturator, and popliteal lymphadenectomy in patients with melanoma. Cutaneous Melanoma 2009, 457-469. St. Louis: Quality Medical Publishing, Inc, Balch CM, Houghton AN, Sober AJ, Soong SJ, 5.
10. Essner R, Scheri R, Kavanagh M, Torisu-Itakura H, Wanek LA, Morton DL. Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection. Arch Surg 2006, 141:877-884. 10.1001/archsurg.141.9.877, 16983031.
11. Sterne GD, Murray DS, Grimely RP. Ilioinguinal block dissection for malignant melanoma. Br J Surg 1995, 83:1057-1059.
12. Balch CM, Durante JR, Bartolucci AA. The impact of surgical quality control in multi-institutional group trials involving adjuvant cancer treatments. Am Surg 1983, 198:164-167.
13. Hughes TM, A'Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg 2000, 87:892-901. 10.1046/j.1365-2168.2000.01439.x, 10931025.
14. Rapaport DP, Stadelmann WK, Reintgen DS. Inguinal lymphadenectomy. Cutaneous melanoma 1998, 209. St. Louis: Quality Medical Publishing, Inc, Balch CM, Houghton A, Sober AJ, Soong SJ, 3.
15. Spillane AJ, Cheung BLH, Winstanley J, Thompson JF. Lymph node ratio provides prognostic information in addition to American joint committee on cancer N stage in patients with melanoma, even if quality of surgery is standardized. Ann Surg 2010, 253:109-115.
16. Xing Y, Badgwell BD, Ross MI. Lymph node ratio predicts disease specific survival in melanoma patients. Cancer 2009, 115:2503-2513.
17. Rossi CR, Mocellin S, Pasquali S. N ratio: a novel independent prognostic factor for patients with Stage III cutaneous melanoma. Ann Surg Oncol 2008, 15:310-315. 10.1245/s10434-007-9641-z, 17987346.
18. Kretschmer L, Neumann C, Preusser KP, Marsch WC. Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin. Acta Oncol 2001, 40:72-78. 10.1080/028418601750071091, 11321665.
19. Morton DL, Wanel L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991, 214:491-501. 10.1097/00000658-199110000-00013, 1358554, 1953101.
20. Strobbe LJA, Jonk A, Hart AAM, Nieweg OE, Kroon BB. Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol 1999, 6:255-262. 10.1007/s10434-999-0255-5, 10340884.
21. Urist MM, Maddox WA, Kennedy JE, Balch CM. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer 1983, 51:2152-2156. 10.1002/1097-0142(19830601)51:11<2152::AID-CNCR2820511134>3.0.CO;2-7, 6839303.
22. Beitsch P, Balch CM. Operative morbidity and risk factor assessment in inguinal lymph node dissection for melanoma patients. Am J Surg 1992, 164:463-466.
23. Poos HPAM, Kruijff S, Bastiaannet E, van Ginkel RJ, Hoekstra HJ. Therapeutic groin dissection for melanoma: risk factors for short term morbidity. Eur J Surg Oncol 2009, 32:877-883.
24. Van Akkoi ACJ, Bouwis MG, van Geel AN, Hoedemaker R, Verhoef C, Grunhagen DJ, Schmitz PI, Eggermont AM, de Wilt JH. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol 2007, 33:102-108. 10.1016/j.ejso.2006.10.032, 17161577.
25. de Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ. Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection with cutaneous melanoma. Eur J Surg Oncol 2006, 32:785-789. 10.1016/j.ejso.2006.05.003, 16806794.
26. Santinami M, Carbone A, Crippa F, Maurichi A, Pellitteri C, Ruggeri R, Zoras O, Patuzzo R. Radical dissection after positive groin sentinel biopsy in melanoma patients: rate of further positive nodes. Melanoma Res 2009, 19:112-118. 10.1097/CMR.0b013e328329fe7d, 19282788.
27. Warso MA. Das Gupta TK: Melanoma recurrence in a previously dissected lymph node basin. Arch Surg 1994, 129:252-255. 10.1001/archsurg.1994.01420270028006, 8129598.
28. Bilimoria KY, Balch CM, Bentrem DJ, Talamonti MS, Ko CY, Lange JR, Winchester DP, Wayne JD. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol 2008, 15:1566-1576. 10.1245/s10434-008-9885-2, 18414952.
29. Hughes TM, Thomas JM. Combined inguinal and pelvic lymph node dissection for Stage III melanoma. Br J Surg 1999, 86:1493-1498. 10.1046/j.1365-2168.1999.01316.x, 10594495.
30. Galliot-Repkat C, Callioid R, Trost O, Danino A, Collet E, Lambert D, Vabres P, Dalac S. The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma. Eur J Surg Oncol 2006, 32:790-794. 10.1016/j.ejso.2006.04.004, 16822643.
31. Miranda EP, Gertner M, Wall J, Grace E, Kashani-Sabet M, Allen R, Leong SP. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004, 139:831-837. 10.1001/archsurg.139.8.831, 15302691.
32. Clark PB, Soo V, Kraas J, Shen P, Levine EA. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 2006, 141:284-288. 10.1001/archsurg.141.3.284, 16549694.
33. van der Ploeg AP, van Akkooi AC, Schmitz PI, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C. Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. Ann Surg Oncol 2011, 18:3300-3308. 10.1245/s10434-011-1741-0, 3192282, 21537867.